Latest news and press releases about Skye Bioscience, Inc. (SKYE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc.
Price
| Price | $1.70 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.49 |
| EV / EBITDA | -0.44 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -279.29% |
| Return on Invested Capital | -286.55% |
| Return on Assets | -197.52% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALGS · BRNS · CVM · INMB · KZR · LVTX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of SKYE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks